Inovio Biomedical Corporation Unveils Skin Electroporation Technology for Delivering DNA Vaccines
SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, today unveiled its new clinical-grade, miniaturized electroporation device designed to be an easy-to-use, portable delivery product for DNA vaccines. Inovio believes the device may be used to inoculate large populations against infectious diseases such as influenza, dengue and malaria. This new skin electroporation technology has been used to deliver DNA vaccines in several preclinical animal models and generated strong, protective antibody responses, which are required to provide immunity against targeted diseases. Dr. Niranjan Sardesai, SVP, Research and Development, introduced this new technology and device in a presentation at Phacilitate Vaccine Forum Washington 2010 on Tuesday, January 26th, in Washington, DC.